Swan Capital LLC Pacira Bio Sciences, Inc. Transaction History
Swan Capital LLC
- $184 Billion
- Q2 2024
A detailed history of Swan Capital LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Swan Capital LLC holds 27 shares of PCRX stock, worth $477. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27Holding current value
$477% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCRX
# of Institutions
273Shares Held
48.4MCall Options Held
378KPut Options Held
1.53M-
Black Rock Inc. New York, NY8.01MShares$141 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$89.8 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.16MShares$38.2 Million0.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.07MShares$36.5 Million0.1% of portfolio
-
State Street Corp Boston, MA1.9MShares$33.6 Million0.0% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $810M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...